

Corporate Fact Sheet

Applied BioMath is a model informed drug discovery and development (MID3) services, software, and R&D company

Systems Modeling

Mechanistic PK/PD
Quantitative Systems Pharmacology

Pharmacometrics

PK/PD
Preclinical & Clinical Pharmacology
PopPK

Bioinformatics

Artificial Intelligence
Machine Learning

Software as a Service

Applied BioMath Assess™*

*Patent Pending

> **74%**

Repeat Business Rate

> **265**

Projects

> **100**

Clients

\$4.75M

NIH & FDA Grant Funding

Areas of impact for systems modeling services throughout R&D

Early Feasibility Assessment (EFA)

Lead Generation

Clinical Candidate Selection

IND

Early Stage Clinical

Late Stage Clinical

Test Therapeutic Concept

Optimal Properties

Experimental Design & Prioritization

Therapeutic Index

Competitor Differentiation

In-licensing Risks

Early Dose Predictions

Species Translation

FIH Dose / Regimen

Indication

Indication Hopping

RP2D

Dose Expansion

Patient Stratification

BLA / NDA

Breadth of Experience

Our interdisciplinary team has a breadth of
pharma and biotech experience

Biochemistry • Applied Math • Chemical Engineering • Biology • Biomedical
Engineering • Computational Biology



170+

Years combined
pharma & biotech
experience



61%

Team members
holding a scientific
doctorate



30+

Posters &
Papers



60+

Employees

Our expertise spans many therapeutic areas and modalities

Therapeutic Areas

- Oncology
- Immuno-oncology
- Inflammation & Immunology
- Infectious Disease
- Respiratory/ Cardiovascular
- CNS/ Alzheimer's Disease
- Metabolic
- Pain
- Rare and Orphan
- Ocular Disease

Modalities

Protein Therapies

- Traditional mAbs
- Antibody-drug Conjugates
- Bispecific Antibodies
- Multi-targeting Biologics
- Peptides
- Fusion Proteins
- Conditionally Active Biologics
- NK Cell Engagers
- T Cell Engagers
- Immunocytokines

Small Molecules

- Irreversible binders
- Prodrugs
- Protein Degraders
- Kinase Inhibitor

Cell & Gene Therapies

- Lipid Nanoparticles
- RNAi
- AAV
- CRISPR/Cas9
- Engineered Message
- CAR-T
- Other Cell Therapies

Services

Our services span throughout the entire drug R&D continuum

Modeling and Simulation

- Mechanistic/Translational PK/PD
- Quantitative Systems Pharmacology
- Quantitative Systems Toxicology
- Platform/Disease Models
- PK/PD
- PBPK
- PopPK
- Exposure Response Modeling
- Clinical Trial Simulations
- Model-based Meta Analysis

Clinical Pharmacology

- Non-compartmental Analyses
- Regulatory Support
- Clinical Trial Design
- Pediatric Development Plans
- Clinical Pharmacology Plans and Gap Analysis

Network and Data-Driven Approaches

- Bioinformatics
- AI/ML
- Biomarker Analysis
- Pathway Analysis
- Target Identification

We support cutting-edge therapies with a variety of clients*


- AbbVie
- Alexion
- Biogen
- Checkpoint
- Codiak
- Compass
- CytomX
- Gritstone
- Ironwood
- Jounce
- KSQ
- Northern Biologics
- Novartis
- Obsidian
- OncoMyx
- Pandion
- Pfizer
- Revitope
- Sanofi
- Shire
- Syntimmune
- Takeda
- Tusk
- Verseau
- Xencor
- Xilio
- Zymeworks

** This is a partial list of clients in the public domain.*


Applied BioMath Assess™

An early feasibility assessment tool for biotherapeutics

Target Engagement Safety




Target Engagement Efficacy



Therapeutic Index

 Safety  Efficacy



✓ **Intuitive graphical user interface with pre-built pharmacology models requires no programming experience**

✓ **Automatic report generation and saved scenario files** enable reproducibility and traceability

✓ Point and click interface **helps inform drug, target, and dose-related questions in real time, such as:**

- How hard will it be to develop the biologic (e.g., affinity, avidity, format, T1/2, dose, dose frequency, uncertainty)?
- Should I expect Target Mediated Drug Disposition (TMDD) with this target?
- Do I already have my Lead(s) or do I need to continue optimizing?
- Should I expect improved affinity or PK to translate to improved dosing?